Psychedelics and the essential importance of context.
Robin Carhart-Harris, Leor Roseman, Eline Haijen, David Erritzøe, Rosalind Watts, Igor Branchi, Mendel Kaelen
Journal of Psychopharmacology February 15, 2018 DOI: 10.1177/0269881118754710 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Opinion piece Peer reviewed |
|---|---|
| Keywords | Psychedelics Hallucinogens Entheogens Psychedelic compounds Mind-altering substances Therapeutic potential Beneficial outcomes Positive results Healing potential Medical applications Treatment potential Therapeutic benefits Beneficial results Set and setting Environment Preparation Context Surroundings Mindset Supportive setting Structured setting Administration care Thoughtful care Crucial insight Essential factors |
| Citations | 646 |
| Key points | Argues that classic psychedelics' effects are exceptionally sensitive to context due to their pharmacological mechanism, and that contextual determinants of the acute experience predict long-term mental health outcomes. |
Abstract
Psychedelic drugs are making waves as modern trials support their therapeutic potential and various media continue to pique public interest. In this opinion piece, we draw attention to a long-recognised component of the psychedelic treatment model, namely ‘set’ and ‘setting’ – subsumed here under the umbrella term ‘context’. We highlight: (a) the pharmacological mechanisms of classic psychedelics (5-HT2A receptor agonism and associated plasticity) that we believe render their effects exceptionally sensitive to context, (b) a study design for testing assumptions regarding positive interactions between psychedelics and context, and (c) new findings from our group regarding contextual determinants of the quality of a psychedelic experience and how acute experience predicts subsequent long-term mental health outcomes. We hope that this article can: (a) inform on good practice in psychedelic research, (b) provide a roadmap for optimising treatment models, and (c) help tackle unhelpful stigma still surrounding these compounds, while developing an evidence base for long-held assumptions about the critical importance of context in relation to psychedelic use that can help minimise harms and maximise potential benefits.
Citations in the library
Cited by 533
- Trial of Psilocybin versus Escitalopram for Depression New England Journal of Medicine April 14, 2021
- REBUS and the Anarchic Brain: Toward a Unified Model of the Brain Action of Psychedelics Pharmacological Reviews June 20, 2019
- Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression Frontiers in Pharmacology January 17, 2018
- Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels Neuropsychopharmacology January 26, 2019
- Increased global integration in the brain after psilocybin therapy for depression. Nature Medicine April 11, 2022
and 528 more in the library
Cites 38
- Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Journal of Psychopharmacology November 30, 2016
- Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial Journal of Psychopharmacology November 30, 2016
- Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance Psychopharmacology July 7, 2006
- Human hallucinogen research: guidelines for safety. Journal of Psychopharmacology July 1, 2008
- Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects. Psychopharmacology December 1, 2011
and 33 more in the library